Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
Add more filters










Publication year range
1.
Protein Expr Purif ; 17(3): 477-84, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10600468

ABSTRACT

Recombinant major capsid protein, L1 (M(r) = 55,000), of human papillomavirus type 11 was expressed intracellularly at high levels in a galactose-inducible Saccharomyces cerevisiae expression system by an HPV6/11 hybrid gene. The capsid protein self-assembled into virus-like particles (VLPs) and accounted for 15% of the total soluble protein. A purification process was developed that consisted of two main steps: microfiltration and cation-exchange chromatography. The purified VLPs were 98% homogeneous, and the overall purification yield was 10%. The final product was characterized by several analytical methods and was highly immunogenic in mice.


Subject(s)
Capsid/biosynthesis , Oncogene Proteins, Viral/biosynthesis , Papillomaviridae/chemistry , Saccharomyces cerevisiae/metabolism , Amino Acids/analysis , Animals , Antibody Formation , Blotting, Western , Capsid/chemistry , Capsid/immunology , Capsid/isolation & purification , Capsid Proteins , Chromatography, Ion Exchange , Enzyme-Linked Immunosorbent Assay , Humans , Mice , Mice, Inbred BALB C , Microscopy, Electron , Oncogene Proteins, Viral/chemistry , Oncogene Proteins, Viral/immunology , Oncogene Proteins, Viral/isolation & purification , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Recombinant Proteins/immunology , Recombinant Proteins/isolation & purification , Virus Assembly
2.
J Biol Chem ; 274(9): 5810-22, 1999 Feb 26.
Article in English | MEDLINE | ID: mdl-10026203

ABSTRACT

The L1 major capsid protein of human papillomavirus (HPV) type 11, a 55-kDa polypeptide, forms particulate structures resembling native virus with an average particle diameter of 50-60 nm when expressed in the yeast Saccharomyces cerevisiae. We show in this report that these virus-like particles (VLPs) interact with heparin and with cell-surface glycosaminoglycans (GAGs) resembling heparin on keratinocytes and Chinese hamster ovary cells. The binding of VLPs to heparin is shown to exhibit an affinity comparable to that of other identified heparin-binding proteins. Immobilized heparin chromatography and surface plasmon resonance were used to show that this interaction can be specifically inhibited by free heparin and dextran sulfate and that the effectiveness of the inhibitor is related to its molecular weight and charge density. Sequence comparison of nine human L1 types revealed a conserved region of the carboxyl terminus containing clustered basic amino acids that bear resemblance to proposed heparin-binding motifs in unrelated proteins. Specific enzymatic cleavage of this region eliminated binding to both immobilized heparin and human keratinocyte (HaCaT) cells. Removal of heparan sulfate GAGs on keratinocytes by treatment with heparinase or heparitinase resulted in an 80-90% reduction of VLP binding, whereas treatment of cells with laminin, a substrate for alpha6 integrin receptors, provided minimal inhibition. Cells treated with chlorate or substituted beta-D-xylosides, resulting in undersulfation or secretion of GAG chains, also showed a reduced affinity for VLPs. Similarly, binding of VLPs to a Chinese hamster ovary cell mutant deficient in GAG synthesis was shown to be only 10% that observed for wild type cells. This report establishes for the first time that the carboxyl-terminal portion of HPV L1 interacts with heparin, and that this region appears to be crucial for interaction with the cell surface.


Subject(s)
Glycosaminoglycans/metabolism , Heparin/metabolism , Keratinocytes/metabolism , Oncogene Proteins, Viral/metabolism , Papillomaviridae/metabolism , Virion/metabolism , Amino Acid Sequence , Animals , CHO Cells , Capsid Proteins , Cell Line , Cell Membrane/metabolism , Cricetinae , Enzyme-Linked Immunosorbent Assay , Glycosaminoglycans/antagonists & inhibitors , Glycosaminoglycans/biosynthesis , Humans , Microscopy, Electron , Molecular Sequence Data , Molecular Weight , Oncogene Proteins, Viral/chemistry , Papillomaviridae/ultrastructure , Polymers , Protein Binding , Recombination, Genetic , Sequence Homology, Amino Acid , Surface Plasmon Resonance , Virion/ultrastructure
3.
Protein Expr Purif ; 13(3): 291-300, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9693053

ABSTRACT

A double mutant of tick anticoagulant peptide (TAP) was cloned as a chimeric fusion with the yeast alpha-mating factor pre-proleader peptide. Expression in yeast (Saccharomyces cerevisiae) resulted in the secretion of the TAP mutein into the culture medium. An HPLC-based assay was used to screen yeast strains to find those giving highest expression levels. Efficiency of cleavage at the junction of the leader-TAP mutein varied from strain to strain, and a rapid purification method followed by N-terminal sequence analysis was used to identify a host strain that minimized undesirable cleavage products. A purification scheme was developed which separated the TAP mutein from improperly processed peptides present in the medium. This scheme employed cation-exchange chromatography and reversed-phase HPLC. Scale-up of the process was successful and produced 100 mg of fully functional TAP mutein of >96% homogeneity from a 50-L yeast culture.


Subject(s)
Peptides/genetics , Saccharomyces cerevisiae/genetics , Amino Acid Sequence , Animals , Arthropod Proteins , Base Sequence , Chromatography, High Pressure Liquid , Chromatography, Ion Exchange , Cloning, Molecular , DNA, Recombinant , Genetic Vectors , Intercellular Signaling Peptides and Proteins , Mating Factor , Molecular Sequence Data , Peptides/isolation & purification , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/isolation & purification , Ticks/genetics
4.
Thromb Haemost ; 79(3): 656-62, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9531058

ABSTRACT

The importance of thrombin in arterial and venous thrombosis renders thrombin inhibition an important therapeutic target. Identification of novel inhibitors requires an appropriate animal model. We modified a previously reported rat arterial thrombosis model to allow simultaneous assessment of the arterial and venous antithrombotic efficacies of heparin, hirudin, hirulog, a novel thrombin inhibitor H-(N-Me-D-Phe)-Pro-L-trans-4-aminocyclohexyl-Gly-[CO-CO]-NHCH3+ ++ (L-370,518) and the factor Xa inhibitor tick anticoagulant peptide in rabbits. Thrombosis was induced through application of 70% ferric chloride to the femoral artery and jugular vein. Incidence of occlusion, thrombus weight, aPTT and plasma inhibitor concentrations were determined. Heparin was efficacious in preventing arterial and venous occlusive thrombosis but at a dose that profoundly elevated aPTT. On a molar dosing basis, the approximate order of potency of the thrombin and factor Xa inhibitors was similar in artery and vein: hirudin>tick anticoagulant peptide>hirulog> or =L-370,518. Data suggested that compounds tended to be more potent in preventing venous thrombosis than arterial. This thrombin-dependent model is an economical and efficient approach to arterial and venous antithrombotic efficacy screening that eliminates variabilities encountered when multiple model/multiple animal strategies are employed.


Subject(s)
Antithrombins/administration & dosage , Hirudins/analogs & derivatives , Hirudins/administration & dosage , Peptide Fragments/administration & dosage , Peptides/administration & dosage , Thrombin/antagonists & inhibitors , Thrombin/metabolism , Thrombosis/drug therapy , Animals , Arteries/pathology , Arthropod Proteins , Disease Models, Animal , Intercellular Signaling Peptides and Proteins , Rabbits , Rats , Recombinant Proteins/administration & dosage , Thrombosis/blood , Thrombosis/pathology , Veins/pathology
5.
J Infect Dis ; 176(5): 1141-5, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9359711

ABSTRACT

It has been shown previously that immunization of animals with recombinant virus-like particles (VLPs) consisting of the viral capsid proteins L1 or L1 plus L2 protected animals against experimental viral challenge. However, none of these experimental models addresses the issue of whether systemic immunization with VLPs elicits a neutralizing antibody response in the genital mucosa. Such a response may be necessary to protect the uterine cervix against infection with genital human papillomavirus (HPV) types. African green monkeys systemically immunized with HPV-11 VLPs expressed in Saccharomyces cerevisiae and formulated on aluminum adjuvant elicited high-titered HPV-11 VLP-specific serum antibody responses. Sera from these immunized monkeys neutralized HPV-11 in the athymic mouse xenograft system. Significant levels of HPV-11-neutralizing antibodies also were observed in cervicovaginal secretions. These findings suggest that protection against HPV infection of the uterine cervix may be possible through systemic immunization with HPV VLPs.


Subject(s)
Antibodies, Viral/blood , Papillomaviridae/immunology , Vaccines, Synthetic/immunology , Vagina/immunology , Viral Vaccines/immunology , Virion/immunology , Animals , Chlorocebus aethiops , Female , Immunity, Mucosal , Immunization , Immunoglobulin G/blood , Saccharomyces cerevisiae/genetics
6.
Thromb Haemost ; 74(2): 640-5, 1995 Aug.
Article in English | MEDLINE | ID: mdl-8585000

ABSTRACT

The antithrombotic efficacies of the coagulation factor Xa inhibitor recombinant tick anticoagulant peptide (rTAP) and heparin were compared in a canine model of left circumflex (LCX) coronary artery electrolytic lesion. Intravenous infusions of saline (controls), rTAP (50 micrograms/kg/min continuous infusion) or heparin (200 U/kg bolus followed by 2 U/kg/min continuous infusion) were started 60 min prior to the initiation of LCX coronary artery electrolytic injury (150 microA continuous anodal current). All 6/6 saline-treated control animals developed occlusive thrombi at 49.8 +/- 13.6 min after the initiation of vessel injury, and possessed a residual thrombus mass of 20.7 +/- 3.3 mg. In the rTAP treatment group, 4/6 preparations developed occlusive thrombi, but with times to thrombosis delayed significantly compared to both the saline control as well as to the heparin treatment group (202.7 +/- 28.9 min; p < 0.01 to both saline and heparin groups). The remaining 2 rTAP-treated preparations remained patent despite the continued electrical stimulation of the coronary vessel for 5 h. Residual thrombus mass in the rTAP treatment group was reduced markedly compared to the saline control group (4.4 +/- 1.0 mg; p < 0.01). Heparin infusion resulted in a modest but statistically insignificant delay in occlusive LCX coronary artery thrombosis compared to saline controls, with all 6/6 heparin-treated preparations occluding at 79.7 +/- 16.5 min after the initiation of vessel injury. Residual thrombus mass in heparin-treated animals, however, was reduced compared to saline controls (9.4 +/- 1.4 mg; p < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Anticoagulants/therapeutic use , Coronary Thrombosis/prevention & control , Factor Xa Inhibitors , Peptides/therapeutic use , Animals , Anticoagulants/blood , Anticoagulants/pharmacology , Arthropod Proteins , Coronary Vessels/injuries , Dogs , Drug Evaluation , Electrolysis/adverse effects , Feasibility Studies , Female , Heparin/pharmacology , Intercellular Signaling Peptides and Proteins , Lip/injuries , Male , Oral Hemorrhage/drug therapy , Peptides/blood , Peptides/pharmacology , Platelet Aggregation/drug effects , Recombinant Proteins/therapeutic use
7.
J Chromatogr B Biomed Appl ; 662(2): 325-34, 1994 Dec 09.
Article in English | MEDLINE | ID: mdl-7536592

ABSTRACT

The chromatographic properties of Superdex 30 prep grade medium have been investigated in non-denaturing and denaturing mobile phases using commercially available proteins and peptides as well as low-molecular-mass (M(r)) recombinant polypeptides. The medium is a macroreticular gel composed of crosslinked agarose beads to which dextran has been covalently bound. The mean particle size is approximately 34 microns. Experimental results show a linear relation between the distribution coefficient (KD) and the log10 M(r) in the fractionation range 24,000-3000. The relationships between resolution and flow-rate or load volume were investigated and shown to be comparable with those of Superdex 75 and 200 prep grade media. Minimal loss of resolution occurred in the flow-range from 30-60 cm/h. Load volumes of up to 5% total column volume could be applied while maintaining baseline resolution of polypeptide mixtures. Non-specific interactions between the matrix and certain samples were characterized. The predominant interactions with the resin appear to be hydrophobic in nature rather than ionic. Hydrogen bonding may also play a role in the retardation of certain small molecules. The applicability of the resin for separating dimeric and oligomeric forms of low-molecular-mass recombinant proteins was shown.


Subject(s)
Peptides/isolation & purification , Recombinant Proteins/isolation & purification , Amino Acid Sequence , Arthropod Proteins , Chromatography , Chromatography, Gel , Dextrans , Guanidines , Intercellular Signaling Peptides and Proteins , Molecular Sequence Data , Molecular Weight , Mutation , Particle Size , Protein Denaturation , Sepharose/analogs & derivatives , Serine Proteinase Inhibitors/isolation & purification
8.
N Engl J Med ; 330(17): 1192-6, 1994 Apr 28.
Article in English | MEDLINE | ID: mdl-8139629

ABSTRACT

BACKGROUND: The presence of a specific cellular receptor is thought to be necessary for susceptibility to viral infection. The erythrocyte P antigen is the cellular receptor for parvovirus B19. We hypothesized that the rare persons with the p phenotype, whose erythrocytes do not have this receptor, would be naturally resistant to B19 infection, which causes erythema infectiosum. METHODS: Blood samples were collected from two populations in cross-sectional studies. We determined the P antigen phenotype of the red cells and tested plasma for anti-B19-specific antibodies. Bone marrow from donors of known P antigen phenotype was inoculated with parvovirus B19. Infectivity was measured by assays of erythroid progenitor cells, dot blot analysis, and in situ hybridization for B19 DNA, and an immunofluorescence assay for viral-capsid proteins. RESULTS: Of the 17 subjects with the p red-cell phenotype, who did not have P antigen on their erythrocytes, none (0 of 11 and 0 of 6) had serologic evidence of previous parvovirus B19 infection. In contrast, the seropositivity rates in the two control groups were 71 percent (53 of 75, P < 0.001) and 47 percent (32 of 68, P = 0.03). In vitro, bone marrow from donors with the p phenotype maintained normal erythropoiesis despite very high concentrations of virus, with no evidence of infection of erythroid progenitor cells by parvovirus B19. CONCLUSIONS: People who do not have P antigen, which is the cellular receptor for parvovirus B19, are naturally resistant to infection with this pathogen.


Subject(s)
Erythema Infectiosum/blood , Erythema Infectiosum/immunology , Isoantigens/immunology , P Blood-Group System/immunology , Adolescent , Adult , Antibodies, Viral/blood , Cells, Cultured , Cross-Sectional Studies , Disease Susceptibility , Erythema Infectiosum/epidemiology , Erythema Infectiosum/microbiology , Erythroid Precursor Cells/microbiology , Humans , Parvovirus B19, Human/immunology , Phenotype
9.
Cardiovasc Res ; 28(1): 78-85, 1994 Jan.
Article in English | MEDLINE | ID: mdl-8111795

ABSTRACT

OBJECTIVE: The aim was to examine the abilities of the direct thrombin inhibitor, recombinant hirudin (rHIR), and the coagulation factor Xa inhibitor, recombinant tick anticoagulant peptide (rTAP), given in combination with rt-PA as high dose front loading plus low dose maintenance infusions, to enhance reperfusion and maintain vessel patency in a canine model of left circumflex coronary artery stenosis and electrolytic lesion. METHODS: Occlusive coronary artery thrombosis was induced in anaesthetised dogs by electrical injury (150 microA) of the intimal surface of the vessel. Thirty minutes after occlusive thrombosis, high dose front loading infusions (45 min) of rTAP (200 micrograms.kg-1 x min-1) and rHIR (300 micrograms.kg-1 x min-1) were initiated concomitant with the start of a 90 min infusion of recombinant tissue-type plasminogen activator (rt-PA). Following the termination of front loading infusions, maintenance infusions of rTAP (10 or 20 micrograms.kg-1 x min-1) or rHIR (20 micrograms.kg-1 x min-1) were initiated and continued for the duration of the protocol (180 min after rt-PA termination). RESULTS: Reperfusion was incomplete in the rHIR group (7/9; 78%), whereas all rTAP-treated preparations reperfused (8/8 per group, aggregate 16/16; 100%). Following thrombolysis, the rHIR group had a high incidence of reocclusion, ranging from intermittent to long periods of occlusion, with only 2/7 (29%) of the preparations which initially recanalised remaining patent during the 180 min period following rt-PA termination. In contrast, 5/8 preparations in each of the two rTAP groups [aggregate 10/16; 63%] remained patent during the same period. The greater efficacy of rTAP v rHIR in maintaining vessel patency was also reflected in integrated coronary artery blood flows [91.0(SEM 5.8)% and 84.9(6.1)% of preocclusion flow in rTAP groups v 57.5(12.2)% of preocclusion flow in rHIR group], times to reocclusion [123.3(22.8) and 128.0(6.7) min in rTAP groups v 36.6(23.2) min in rHIR group; p < 0.05], and residual thrombus masses [1.8(0.3) and 2.0(0.3) mg in rTAP groups v 10.4(3.8) mg in rHIR group; p < 0.05]. CONCLUSIONS: With the present front loading plus low dose maintenance infusions designed to limit the duration of "high dose" conjunctive therapy, rTAP was more effective than rHIR at equimolar plasma concentrations in maintaining post-thrombolysis vessel patency, preserving coronary artery blood flow, and reducing residual thrombus mass. These findings further support the therapeutic potential of inhibiting factor Xa in the setting of coronary artery thrombolysis.


Subject(s)
Coronary Disease/drug therapy , Factor Xa Inhibitors , Hirudin Therapy , Peptides/therapeutic use , Thrombolytic Therapy , Tissue Plasminogen Activator/therapeutic use , Vascular Patency/drug effects , Animals , Arthropod Proteins , Dogs , Drug Administration Schedule , Drug Therapy, Combination , Female , Intercellular Signaling Peptides and Proteins , Male , Recombinant Proteins/therapeutic use , Recurrence , Time Factors
10.
Protein Expr Purif ; 4(3): 247-55, 1993 Jun.
Article in English | MEDLINE | ID: mdl-8518563

ABSTRACT

Hirudin (HIR), derived from leeches, and tick anticoagulant peptide (TAP) are polypeptide protease inhibitors of thrombin and coagulation factor Xa (fXa), respectively, and they have both shown utility in vitro and in vivo as potent antithrombotic agents. A thorough side-by-side comparison of the in vivo efficacy of factor Xa inhibition compared to thrombin inhibition by TAP and HIR, respectively, required purification and characterization of multigram amounts of hirudin. Therefore, a recombinant Saccharomyces cerevisiae strain was developed using a plasmid containing the gene encoding the MF alpha 1 preproleader, a synthetic hybrid HV1-HV2 HIR gene, and a galactose-inducible promoter which directed the secretion of 44 mg/liter of recombinant HIR (rHIR) after induction. rHIR was purified by a process that consisted of two chromatographic steps and decolorization. Total yield for the purification process was 3.6 g, or 41%. This process gave 59-fold purification of rHIR that was judged to be > 96% pure with regard to polypeptide content by capillary zonal electrophoresis and reversed-phase high-performance liquid chromatography. Single, unique N- and C-termini were obtained by sequencing and were identical to those predicted from the deduced sequence of the cDNA. Determination of the dissociation constant, by thrombin:hirudin inhibition reaction, and anticoagulant activity, by the activated partial thromboplastin time, demonstrated that the hybrid rHIR HV1-HV2 protein discussed in this report was essentially equipotent with rHIR preparations HV1 and HV2 reported by others.


Subject(s)
Hirudins/biosynthesis , Amino Acid Sequence , Base Sequence , Carboxypeptidases/metabolism , Cathepsin A , Cloning, Molecular , Gene Expression , Genes, Synthetic/genetics , Genetic Variation , Hirudins/genetics , Hirudins/isolation & purification , Hirudins/metabolism , Hirudins/pharmacology , Molecular Sequence Data , Peptide Fragments , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/isolation & purification , Recombinant Fusion Proteins/pharmacology , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae Proteins , Sequence Analysis , Thrombin/antagonists & inhibitors
11.
Biotechnology (N Y) ; 11(2): 207-12, 1993 Feb.
Article in English | MEDLINE | ID: mdl-7763373

ABSTRACT

Tick anticoagulant peptide (TAP) is a 60 amino acid peptide (Mr = 6977, pI = 4.9) found in the saliva of the soft tick Ornithodorous moubata that specifically inhibits blood coagulation factor Xa (fXa). A recombinant form of TAP (rTAP) secreted by Saccharomyces cerevisiae was purified from 200 liters of fermentation broth with POROS, strong cation exchange (SCX) and reversed-phase high performance liquid perfusion chromatography (RP-HPLC) media (20 microns nominal particle diameter). The higher linear flow rates and dynamic capacities, as well as low back pressures, obtained with perfusion chromatography media permitted 37.5 g of rTAP to be efficiently captured and significantly enriched from 400 liters of diafiltered fermentation broth (24.3 g yield) with 1.25 liter of SCX media using a low pressure column and peristaltic pump in 4.5 hours. Subsequently, 16.7 g of rTAP obtained from the capture step was purified in a high-resolution mode with the same SCX media, after the media was cleaned and repacked into an 800 ml high-pressure column. By doing multiple rapid cycles at high linear flow rates, preparative-scale high-resolution purification of multi-gram amounts of the peptide was done on this relatively small column in only 10.5 hours. Finally, the peptide was desalted and decolorized on a 200 ml RP-HPLC column of perfusion chromatography media by doing multiple rapid cycles. After lyophilization, 12 g of peptide (46.9% yield) was obtained that was > 96% homogeneous by several analytical criteria and fully active in inhibiting blood coagulation factor Xa (fXa).(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Chromatography, High Pressure Liquid , Peptides/isolation & purification , Amino Acid Sequence , Animals , Arthropod Proteins , Chromatography, High Pressure Liquid/methods , Chromatography, Ion Exchange , Fermentation , Genes, Synthetic , Intercellular Signaling Peptides and Proteins , Mating Factor , Molecular Sequence Data , Peptides/genetics , Protein Sorting Signals/genetics , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification , Saccharomyces cerevisiae , Ticks
12.
J Chromatogr ; 574(2): 225-35, 1992 Feb 14.
Article in English | MEDLINE | ID: mdl-1618954

ABSTRACT

Recombinant tick anticoagulant peptide (r-TAP), a potent and specific inhibitor of blood coagulation factor Xa, was purified to greater than 99% homogeneity at the multi-gram scale. Genetically engineered yeast secreted 200-250 mg/l of the heterologous protein into the medium. Cells were separated from broth by diafiltration and purification was done by two chromatographic steps, both conducive to operation on a large scale. Analysis of the purified protein by several methods indicated that it was greater than 99% homogeneous and no incompletely processed or truncated proteins were detected. Physico-chemical characterization data of r-TAP show that it exists as a monomer in solution and no evidence of post-translational modification was observed. The purified protein was fully active in inhibiting human coagulation factor Xa.


Subject(s)
Peptides/isolation & purification , Amino Acid Sequence , Arthropod Proteins , Chromatography, High Pressure Liquid , Electrophoresis, Polyacrylamide Gel , Factor Xa Inhibitors , Fermentation , Genes, Synthetic , Humans , Intercellular Signaling Peptides and Proteins , Isoelectric Focusing , Mass Spectrometry , Molecular Sequence Data , Peptides/genetics , Peptides/metabolism , Peptides/pharmacology , Plasmids , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , Recombinant Proteins/pharmacology , Saccharomyces cerevisiae/metabolism
13.
AIDS Res Hum Retroviruses ; 6(11): 1247-50, 1990 Nov.
Article in English | MEDLINE | ID: mdl-2127681

ABSTRACT

Yeast-expressed p55 precursor core protein of human immunodeficiency virus type 1 (HIV-1) was used to immunize chimpanzees. The animals developed high titers of antibodies to p55 as well as to the p24 and p17 mature cleavage products of the core precursor. Virus-neutralizing antibodies were not elicited. The induced immune responses did not prevent establishment of HIV-1 infection following challenge of one immunized chimpanzee with live virus.


Subject(s)
Gene Products, gag/immunology , HIV Antibodies/biosynthesis , HIV Antigens/immunology , HIV Infections/immunology , Protein Precursors/immunology , Animals , Gene Products, gag/genetics , HIV Core Protein p24 , HIV Envelope Protein gp41/immunology , HIV Infections/prevention & control , Immunization , Neutralization Tests , Pan troglodytes , Protein Precursors/genetics , Recombinant Proteins/immunology , Saccharomyces cerevisiae/genetics , Viral Core Proteins/immunology
14.
J Virol Methods ; 14(1): 25-35, 1986 Aug.
Article in English | MEDLINE | ID: mdl-2945830

ABSTRACT

Hepatitis B micelles containing the p25 component of hepatitis B surface antigen (HBsAg) have been produced by Triton X-100 solubilization followed by ultracentrifugation in linear sucrose gradients. The product was found to resemble micelle forms prepared from plasma-derived HBsAg with the surface being composed of discrete globular and stranded sub-units. The degree of immunochemical relatedness of the micellular preparation was compared to the native 22-nm HBsAg particle present in either plasma or yeast cell extracts. The yeast micelle preparation competed for anti-HBs in a similar manner as intact HBsAg of plasma origin. Enhanced immunogenicity may be expected for micelles containing a recombinant HBsAg protein as has previously been shown for the plasma-derived antigen.


Subject(s)
Colloids , Hepatitis B Surface Antigens/immunology , Micelles , Centrifugation, Density Gradient , Chromobox Protein Homolog 5 , Electrophoresis, Polyacrylamide Gel , Hepatitis B Surface Antigens/genetics , Hepatitis B Vaccines , Hepatitis B virus/immunology , Humans , Microscopy, Electron , Molecular Weight , Peptides/immunology , Radioimmunoassay , Saccharomyces cerevisiae/genetics , Viral Hepatitis Vaccines
15.
Proc Natl Acad Sci U S A ; 82(20): 6830-4, 1985 Oct.
Article in English | MEDLINE | ID: mdl-2931722

ABSTRACT

Hepatitis B surface antigen (HBsAg) has been extracted from yeast cells that produce HBsAg. These cells contain the gene for surface antigen carried on a plasmid that replicates in the cells. Analysis of the yeast-derived HBsAg by sucrose gradient centrifugation and by polyacrylamide gel electrophoresis shows that the antigen that is initially released from yeast cells is a high molecular weight aggregate of the fundamental Mr 25,000 subunit. Unlike HBsAg derived from human plasma, the yeast antigen is held together by noncovalent interactions and can be dissociated in 2% NaDodSO4 without the use of reducing agents. During in vitro purification of the yeast antigen, some disulfide bonds form spontaneously between the antigen subunits, resulting in a particle composed of a mixture of monomers and disulfide-bonded dimers. Treatment with 3 M thiocyanate converts the 20-nm particles into a fully disulfide-bonded form that is not disrupted in NaDodSO4 unless a reducing agent is added. This disulfide-bonded particle resembles the naturally occurring, plasma-derived surface antigen particle, and the in vitro formed particle has been used to prepare a vaccine for humans against hepatitis B virus infection.


Subject(s)
Hepatitis B Surface Antigens/genetics , Recombinant Proteins/genetics , Saccharomyces cerevisiae/genetics , Alcohol Dehydrogenase , Alcohol Oxidoreductases/genetics , Genes , Genes, Fungal , Genes, Viral , Glyceraldehyde-3-Phosphate Dehydrogenases/genetics , Hepatitis B Surface Antigens/isolation & purification , Humans , Plasmids , Promoter Regions, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...